Experiencia argentina del uso compasivo de osimertinib

José N. Minatta; Lorena Lupinacci; Gonzalo Recondo; Susana Sena; Gastón Boggio; Alejandro Muggeri; Carlos Rosenbrock; Federico Cayol; Martín Ángel; Miguel Muñoz; Susana Berutti; Nicolás Castagneris; Dolores Gómez Bradley; José M. Lastiri

doi:10.56969/oc.v23i2.57

Autores/as

José N. Minatta Hospital Italiano, Buenos Aires https://orcid.org/0000-0002-3531-1920
Lorena Lupinacci Sección Oncología, Hospital Italiano de Buenos Aires
Gonzalo Recondo Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC)
Susana Sena Hospital Alemán, Buenos Aires https://orcid.org/0000-0002-4511-6395
Gastón Boggio Sanatorio Parque, Rosario, Santa Fe
Alejandro Muggeri FLENI, Buenos Aires
Carlos Rosenbrock CEMO, Paraná, Entre Ríos
Federico Cayol Sección de Oncología Clínica, Hospital Italiano de Buenos Aires https://orcid.org/0000-0001-9794-2173
Martín Ángel Instituto Alexander Fleming, Buenos Aires https://orcid.org/0000-0002-1463-8887
Miguel Muñoz Oncología, Rosario, Santa Fe
Susana Berutti Hospital Italiano de La Plata, Buenos Aires
Nicolás Castagneris Clínica Sucre, Córdoba
Dolores Gómez Bradley Sección Oncología, Hospital Italiano de Buenos Aires
José M. Lastiri Hospital Italiano, Buenos Aires

DOI:

https://doi.org/10.56969/oc.v23i2.57

Palabras clave:

osimertinib, cáncer de pulmón, mutaciones, receptor del factor de crecimiento epidérmico, lung cancer, mutations, epidermal growth factor receptor

Resumen

El osimertinib es un inhibidor irreversible de tercera generación de tirosina quinasa (ITK) del receptor del factor de crecimiento epidérmico (EGFR), y de la mutación de resistencia T790M del EGFR. Está indicado para el tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico metastásico cuyos tumores tienen deleciones del exón 19 del EGFR o mutaciones L858R del exón 21.

También está indicado para el tratamiento de pacientes con cáncer de pulmón de células no pequeñas (CPCNP) metastásico con mutación detectable de T790M, cuya enfermedad ha progresado durante el tratamiento con inhibidores de tirosina quinasa EGFR (TKI).

Evaluamos la seguridad y eficacia de osimertinib en el uso compasivo de pacientes diagnosticados con cáncer de pulmón avanzado, con mutación de EGFR y que progresaron a terapia previa con inhibidores de tirosina quinasa y en el momento de la progresión presentaban la mutación de resistencia T790m y/o tenían esta mutación de novo.

Citas

Alsharedi M, Bukamur H, Elhamdani A. Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer. Drugs Today (Barc) 2018; 54:369-79. DOI: https://doi.org/10.1358/dot.2018.54.6.2817668

Bollinger MK, Agnew AS, Mascara GP. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract 2018; 24:379-88. DOI: https://doi.org/10.1177/1078155217712401

Yang JC, Ahn MJ, Kim DW. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA Study Phase II Extension Component. J Clin Oncol 2017; 35:1288-96. DOI: https://doi.org/10.1200/JCO.2016.70.3223

Aguiar F, Fernandes G, Queiroga H, et al.Overall survival analysis and characterization of an EGFR mutated non-small cell lung cancer (NSCLC) population. Arch Bronconeumol 2018; 54:10-1. DOI: https://doi.org/10.1016/j.arbres.2017.07.012

Greenhalgh J, Dwan K, Boland A, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 2016; CD010383. doi: 10.1002/14651858. CD010383.pub2. DOI: https://doi.org/10.1002/14651858.CD010383.pub2

Fassunke J, Ihle MA, Lenze D, et al. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. Virchows Arch 2017; 471:509-20. DOI: https://doi.org/10.1007/s00428-017-2226-8

Hijmering-Kappelle LBM, van der Wekken AJ, Hiltermann TJN, Groen HJM. New biopsy at lung cancer progression: rational treatment of resistant lung cancer. Ned Tijdschr Geneeskd 2017; 161:D1229.

Suda K, Onozato R, Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 2009; 4:1-4. DOI: https://doi.org/10.1097/JTO.0b013e3181913c9f

Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med 2017; 5:46. DOI: https://doi.org/10.21037/atm.2017.01.32

Liu Y, Sun L, Xiong ZC, et al. Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs. Onco Targets Ther 2017; 10: 2267-79. DOI: https://doi.org/10.2147/OTT.S133082

Liao BC, Lin CC, Yang JC Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2015; 27:94-101. DOI: https://doi.org/10.1097/CCO.0000000000000164

Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med 2018; 378:113-25. DOI: https://doi.org/10.1056/NEJMoa1713137

Fujiwara Y, Goto Y, Kanda S, et al. Efficacy and safety of osimertinib in a Japanese compassionate use program. Jpn J Clin Oncol 2017; 47:625-9. DOI: https://doi.org/10.1093/jjco/hyx050